About Cyclin-dependent kinase 9
Cyclin-dependent kinase 9 (CDK9) is a protein
from Homo sapiens identified by UniProt accession
P50750, 372 residues long.
MolForge cross-references it against 0 known binders and
296 disease associations.
Target properties
| Protein name | Cyclin-dependent kinase 9 |
| UniProt accession | P50750 |
| Gene | CDK9 |
| Organism | Homo sapiens |
| Length | 372 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (10)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (296)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.59
- Global developmental delay · score 0.42
- choanal atresia · score 0.42
- Abnormality of vision · score 0.42
- Preauricular skin tag · score 0.42
- Abnormality of the ear · score 0.42
- disease of genitourinary system · score 0.42
- Developmental cataract · score 0.42
- Hearing impairment · score 0.42
- Intellectual disability · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50750-F1 | alphafold | PREDICTED | 86.82 | — |
Amino-acid sequence (372 residues)
MAKQYDSVEC PFCDEVSKYE KLAKIGQGTF GEVFKARHRK TGQKVALKKV LMENEKEGFP ITALREIKIL QLLKHENVVN LIEICRTKAS PYNRCKGSIY LVFDFCEHDL AGLLSNVLVK FTLSEIKRVM QMLLNGLYYI HRNKILHRDM KAANVLITRD GVLKLADFGL ARAFSLAKNS QPNRYTNRVV TLWYRPPELL LGERDYGPPI DLWGAGCIMA EMWTRSPIMQ GNTEQHQLAL ISQLCGSITP EVWPNVDNYE LYEKLELVKG QKRKVKDRLK AYVRDPYALD LIDKLLVLDP AQRIDSDDAL NHDFFWSDPM PSDLKGMLST HLTSMFEYLA PPRRKGSQIT QQSTNQSRNP ATTNQTEFER VF
Explore Cyclin-dependent kinase 9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets